- |||||||||| Aplidin (plitidepsin) / PharmaMar, Roche
Enrollment closed, Enrollment change, Trial completion date, Trial primary completion date: Neptuno: Trial to Determine the Efficacy/Safety of Plitidepsin vs Control in Patients With Moderate COVID-19 Infection (clinicaltrials.gov) - Feb 21, 2023 P3, N=205, Active, not recruiting, Not yet recruiting --> Recruiting Recruiting --> Active, not recruiting | N=609 --> 205 | Trial completion date: Dec 2023 --> Mar 2023 | Trial primary completion date: Dec 2023 --> Mar 2023
- |||||||||| Blincyto (blinatumomab) / Astellas, Amgen, Opdivo (nivolumab) / BMS, Imbruvica (ibrutinib) / AbbVie, J&J
Trial termination: Ibrutinib, Nivolumab and Blinatumomab in Richter Transformation (clinicaltrials.gov) - Feb 17, 2023 P2, N=9, Terminated, Recruiting --> Active, not recruiting | N=609 --> 205 | Trial completion date: Dec 2023 --> Mar 2023 | Trial primary completion date: Dec 2023 --> Mar 2023 Completed --> Terminated; The study was closed for slow accrual
- |||||||||| abiraterone acetate / Generic mfg.
Trial completion date, Trial primary completion date: Androgen Reduction in Congenital Adrenal Hyperplasia, Phase 1 (clinicaltrials.gov) - Feb 17, 2023 P1, N=36, Active, not recruiting, Completed --> Terminated; The study was closed for slow accrual Trial completion date: Jan 2023 --> Jan 2024 | Trial primary completion date: Jan 2023 --> Jan 2024
- |||||||||| prednisolone / Generic mfg.
Trial completion date, Trial primary completion date: Intraorbital Injection Versus Oral Steroid in Anterior Idiopathic Orbital Inflammation (clinicaltrials.gov) - Feb 16, 2023 P3, N=120, Recruiting, SOCS3 downregulation mediated by miR-218-5p increases osteoblast differentiation to alleviate POP. Trial completion date: Jun 2023 --> Jun 2025 | Trial primary completion date: Jun 2022 --> Jun 2024
- |||||||||| pantoprazole / Generic mfg., dexamethasone / Generic mfg.
Retrospective data, Journal: An interval of clinically silent gastrointestinal bleed in dysautonomic spinal cord injury: a case report. (Pubmed Central) - Feb 16, 2023 This case illustrates the possibility of an interval in which the patient was bleeding, with the sole indicator being an elevated BUN. Our case calls for closer monitoring of and vigilance for tSCI patients, and possibly employment of different strategies to reduce the incidence and enhance early detection of GIB in tSCI patients to subsequently decrease the morbidity and mortality associated with it.
- |||||||||| dexamethasone / Generic mfg.
Journal: Epigenetic programming of TBX2/CX43 mediates lower sperm quality in male offspring induced by prenatal dexamethasone exposure. (Pubmed Central) - Feb 15, 2023 Further, a series of Sertoli cell interventions confirmed that dexamethasone promoted GR to recruit P300, increased the H3K9ac level of TBX2 promoter region and its expression, and inhibited the expression of CX43. This study confirmed that PDE decreased sperm quality of male offspring, which is related to the epigenetic programming of TBX2/CX43 in the Sertoli cells, provided a theoretical and experimental basis for guiding the rational use of drugs during pregnancy.
- |||||||||| hydrocortisone / Generic mfg.
Journal: When an adrenal crisis disguises itself as a viral gastroenteritis (Pubmed Central) - Feb 15, 2023 A detailed interview revealed that the patient had been taking daily hydrocortisone to treat panhypopi-tuitarism secondary to past traumatic brain injury. The diagnosis of stress-induced adrenal insufficiency was finally retained.
- |||||||||| dexamethasone / Generic mfg.
Journal: Clock genes are expressed in cementum and regulate the proliferation and mineralization of cementoblasts. (Pubmed Central) - Feb 15, 2023 OCCM-30 cells, an immortalized cementoblast cell line, were synchronized with dexamethasone...The present study confirmed the presence of clock genes in the cementum, where they potentially participate in cell proliferation and mineralization. Our findings may inspire new research directions for periodontal regeneration via clock gene manipulation.
- |||||||||| verapamil / Generic mfg., prednisolone / Generic mfg., sumatriptan succinate / Generic mfg.
Journal: Clinical Profile of Chronic Cluster Headaches in a Regional Headache Center in Japan. (Pubmed Central) - Feb 15, 2023 Conclusions CCH remains refractory to treatment. Improving treatment outcomes will require maximizing the use of currently available drugs and expanding the use of neuromodulation, nerve block, and CGRP-targeted therapies.
- |||||||||| pemetrexed / Generic mfg.
Trial primary completion date: Intrathecal Pemetrexed for Leptomeningeal Metastasis (clinicaltrials.gov) - Feb 15, 2023 P1/2, N=40, Recruiting, Improving treatment outcomes will require maximizing the use of currently available drugs and expanding the use of neuromodulation, nerve block, and CGRP-targeted therapies. Trial primary completion date: Dec 2022 --> Mar 2023
- |||||||||| Carvykti (ciltacabtagene autoleucel) / J&J
Trial completion date, CAR T-Cell Therapy, IO biomarker: CARTITUDE-4: A Study Comparing JNJ-68284528, a CAR-T Therapy Directed Against B-cell Maturation Antigen (BCMA), Versus Pomalidomide, Bortezomib and Dexamethasone (PVd) or Daratumumab, Pomalidomide and Dexamethasone (DPd) in Participants With Relapsed and Lenalidomide-Refractory Multiple Myeloma (clinicaltrials.gov) - Feb 15, 2023 P3, N=419, Active, not recruiting, Trial completion date: Mar 2024 --> Aug 2024 | Trial primary completion date: Mar 2024 --> Aug 2024 Trial completion date: Apr 2026 --> Jun 2027
- |||||||||| Darzalex (daratumumab) / J&J
Enrollment open: A Study of Daratumumab (clinicaltrials.gov) - Feb 15, 2023 P3b, N=400, Recruiting, Not yet recruiting --> Recruiting Not yet recruiting --> Recruiting
- |||||||||| Airsupra (budesonide/salbutamol) / AstraZeneca, Avillion, albuterol sulfate metered dose inhaler (PT007) / AstraZeneca
Enrollment closed, Trial completion date, Trial primary completion date: PT027 Compared to PT007 in Patients With Asthma With Mannitol-induced Acute Airway Obstruction (clinicaltrials.gov) - Feb 15, 2023 P3, N=76, Active, not recruiting, Not yet recruiting --> Recruiting Recruiting --> Active, not recruiting | Trial completion date: May 2023 --> Oct 2023 | Trial primary completion date: May 2023 --> Dec 2022
|